Gossamer Bio (#GOSS) announced a structured private placement of up to $250 million, including $150 million of committed capital, to support development of seralutinib through potential FDA approval. The financing provides additional capital to advance the company's lead pulmonary arterial hypertension program. Sector: Biotechnology / Pharmaceuticals Key Highlights 💰 Structured private placement of up to $250M 💵 $150M of committed capital 🧪 Funding dedicated to seralutinib 🎯 Capital supports development toward potential FDA approval 🚀 Strengthens funding runway for the lead program 🫁 Seralutinib remains central to Gossamer's clinical strategy Why It Matters The additional financing reduces near-term funding pressure and provides Gossamer with capital to advance seralutinib toward a potential regulatory milestone, although investors should continue to watch clinical and regulatory execution. Read More: https://www.thinksabio.com/reports/isr/GOSS